吉非替尼对比长春瑞滨联合顺铂辅助治疗II-IIIA期(N1-N2)EGFR突变NSCLC:CTONG1104三期试验最终总生存分析
ADJUVANT-CTONG1104随机III期试验纳入222例完全切除的II-IIIA期(N1-N2)EGFR突变NSCLC患者,1:1随机接受吉非替尼(24个月)或长春瑞滨+顺铂(4周期)。
要点
- 吉非替尼组中位OS达75.5个月,为同类人群历史数据中较长者。
- 疾病进展后后续靶向治疗与OS改善强相关(HR=0.23, 95%CI 0.14-0.38)。
核心结论
- 辅助吉非替尼相比长春瑞滨联合顺铂在II-IIIA期(N1-N2)EGFR突变NSCLC中显著改善DFS,但最终分析未显示OS显著差异。
研究设计与样本
- 随机III期试验(ADJUVANT-CTONG1104, NCT01405079),2011年9月至2014年4月从27个中心入组222例,1:1随机接受吉非替尼(n=111)或VP(n=111)。
- 吉非替尼口服24个月,VP每3周一次共4周期;主要终点为ITT人群DFS,次要终点包括OS、3年和5年DFS率及5年OS率。
主要发现
- 进展后接受后续治疗的患者比例分别为68.4%和73.6%,后续靶向治疗对比无后续治疗与OS改善相关(HR=0.23, 95%CI 0.14-0.38)。
关键数值与推荐
- 入组标准:完全切除的II-IIIA期(N1-N2)NSCLC且EGFR激活突变。
- 吉非替尼用法:口服24个月;VP方案:每3周一次共4周期。
临床怎么用
- 对于II-IIIA期(N1-N2)EGFR突变NSCLC术后患者,辅助吉非替尼仍是改善DFS的选择,但需告知OS未显著获益。
- 疾病进展后应积极给予后续靶向治疗,因其与OS改善强相关。
局限性
- 事后分析后续治疗数据,可能存在混杂因素。
- 样本量有限(222例),OS差异未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: ADJUVANT-CTONG1104 (ClinicalTrials.gov identifier: NCT01405079), a randomized phase III trial, showed that adjuvant gefitinib treatment significantly improved disease-free survival (DFS) versus vinorelbine plus cisplatin (VP) in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC). Here, we report the final overall survival (OS) results. METHODS: From September 2011 to April 2014, 222 patients from 27 sites were randomly assigned 1:1 to adjuvant gefitinib (n = 111) or VP (n = 111). Patients with resected stage II-IIIA (N1-N2) NSCLC and EGFR-activating mutation were enrolled, receiving gefitinib for 24 months or VP every 3 weeks for four cycles. The primary end point was DFS (intention-to-treat [ITT] population). Secondary end points included OS, 3-, 5-year (y) DFS rates, and 5-year OS rate. Post hoc analysis was conducted for subsequent therapy data. RESULTS: Median follow-up was 80.0 months. Median OS (ITT) was 75.5 and 62.8 months with gefitinib and VP, respectively (hazard ratio [HR], 0.92; 95% CI, 0.62 to 1.36; P = .674); respective 5-year OS rates were 53.2% and 51.2% (P = .784). Subsequent therapy was administered upon progression in 68.4% and 73.6% of patients receiving gefitinib and VP, respectively. Subsequent targeted therapy contributed most to OS (HR, 0.23; 95% CI, 0.14 to 0.38) compared with no subsequent therapy. Updated 3y DFS rates were 39.6% and 32. 5% with gefitinib and VP (P = .316) and 5y DFS rates were 22. 6% and 23.2% (P = .928), respectively. CONCLUSION: Adjuvant therapy with gefitinib in patients with early-stage NSCLC and EGFR mutation demonstrated improved DFS over standard of care chemotherapy. Although this DFS advantage did not translate to a significant OS difference, OS with adjuvant gefitinib was one of the longest observed in this patient group compared with historic data.
引用
- Zhong WZ, Wang Q, Mao WM, et al. Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. J Clin Oncol. 2020. PMID: 33332190. doi:10.1200/JCO.20.01820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。